Auro Laboratories Ltd. Stock Analysis 530233.BO

Auro Laboratories Ltd. engages in the business of dealing active pharmaceutical ingredients. The company is headquartered in Mumbai, Maharashtra and currently employs 55 full-time employees. The firm is specializing in producing anti-diabetics like Metformin HCL, which is used in the treatment of type 2 diabetes. The company also undertakes toll/custom manufacturing for API's and intermediates on a contract basis. The firm's API products include antihistamine, muscle relaxant, diuretic, iron deficiency, anti-diabetics, anti-fungal, anti-ulcer, iodine supplement, anti-malaria, analgesics, antacids, anti-inflammatory, specialty chemicals and others. Its intermediate products include glibenclamde sulphonamide, cis-bramo benzoate, cls-tosylate, 2-ethoxy benzoic acid, 2-ethoxy benzoic acid, among others. The company offers its manufacturing and technical services, such as process scale up, process optimization, custom synthesis and custom manufacturing. The company exports to Southeast Asia, Middle East and several European countries.